Imugene Ltd has released a press release.
Imugene Receives $6.54 million R&D Tax Incentive
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- South Korea HERVaxx Patent Grant
- Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx
- FDA ind approval for the phase 2 clinical trial of her-vaxx
- Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc
- S&P DJI Announces December 2021 Quarterly Rebalance
Later from Imugene
- HER-Vaxx Immunotherapy Patent Granted in Europe
- PD1-Vaxx Clinical Trial Supply Agreement with Roche
- Oncolytic Virotherapy CF33 Patent Granted in Japan
- Imugene HER-Vaxx Clinical Trial Collaboration with Merck
- Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene